Update on gastroesophageal reflux disease

被引:5
作者
Serra Pueyo, Jordi [1 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, CIBERehd, Unidad Motilidad & Trastornos Func Digest, Serv Aparato Digest, Barcelona, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2014年 / 37卷 / 02期
关键词
Gastroesophageal reflux; Acid pocket; Impedance; Alginate; PROTON PUMP INHIBITORS; LOWER ESOPHAGEAL SPHINCTER; RANDOMIZED CLINICAL-TRIAL; GABA(B) AGONIST BACLOFEN; ACID POCKET; HIATUS-HERNIA; SYMPTOMS; PREVALENCE; EFFICACY; HEARTBURN;
D O I
10.1016/j.gastrohep.2013.11.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastroesophageal reflux disease is a highly frequent disorder classically characterized by the presence of heartburn and/or acid regurgitation that improves with drug therapy that reduces acid content in the stomach. However, especially in patients with non-erosive disease, response to proton pump inhibitors is unsatisfactory in approximately 1 out of 3 patients, and consequently, in these patients, it is important to establish a definitive diagnosis and an alternative therapeutic strategy. In the last few years, advances have been made in knowledge of the physiopathology of reflux, such as identification of the role of the acid pocket in producing reflux, technological advances that allow differentiation among acid reflux, non-acid reflux and slightly acid reflux, and advances in the treatment of reflux with drugs that attempt to act on the barrier function of the esophagogastric junction. (C) 2013 Elsevier Espana, S.L. and AEEH y AEG. All rights reserved.
引用
收藏
页码:73 / 82
页数:10
相关论文
共 48 条
  • [1] Asociacion Espanola de Gastroenterologia, 2007, PROGR EL GUIAS PRACT
  • [2] The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD
    Beaumont, Hanneke
    Bennink, Roelof J.
    de Jong, Jan
    Boeckxstaens, Guy E.
    [J]. GUT, 2010, 59 (04) : 441 - 451
  • [3] Review article: the pathophysiology of gastro-oesophageal reflux disease
    Boeckxstaens, G. E. E.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (02) : 149 - 160
  • [4] A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial
    Boeckxstaens, Guy E.
    Beaumont, Hanneke
    Hatlebakk, Jan G.
    Silberg, Debra G.
    Bjorck, Karin
    Karlsson, Maria
    Denison, Hans
    [J]. GUT, 2011, 60 (09) : 1182 - 1188
  • [5] Determinants of perception of heartburn and regurgitation
    Bredenoord, AJ
    Weusten, BLAM
    Curvers, WL
    Timmer, R
    Smout, AJPM
    [J]. GUT, 2006, 55 (03) : 313 - 318
  • [6] Gastro-oesophageal reflux disease
    Bredenoord, Albert J.
    Pandolfino, John E.
    Smout, Andre J. P. M.
    [J]. LANCET, 2013, 381 (9881) : 1933 - 1942
  • [7] Multivariate analysis of pathophysiological factors in reflux oesophagitis
    Cadiot, G
    Bruhat, A
    Rigaud, D
    Coste, T
    Vuagnat, A
    Benyedder, Y
    Vallot, T
    LeGuludec, D
    Mignon, M
    [J]. GUT, 1997, 40 (02) : 167 - 174
  • [8] Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease
    Ciccaglione, AF
    Marzio, L
    [J]. GUT, 2003, 52 (04) : 464 - 470
  • [9] Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket
    Clarke, A. T.
    Wirz, A. A.
    Manning, J. J.
    Ballantyne, S. A.
    Alcorn, D. J.
    McColl, K. E. L.
    [J]. GUT, 2008, 57 (03) : 292 - 297
  • [10] Effectiveness of Proton Pump Inhibitors in Nonerosive Reflux Disease
    Dean, Bonnie B.
    Gano, Anacleto D., Jr.
    Knight, Kevin
    Ofman, Joshua J.
    Fass, Ronnie
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (08) : 656 - 664